desert rock formation

Find a Scientist

Yong Hwan Kim

Yong Hwan Kim, PhD

Assistant Professor
Neurobiology

Yong Hwan Kim, PhD, is an assistant professor in the Department of Neurobiology at Barrow Neurological Institute. He works in the Barrow Aneurysm and AVM Research Center.

Dr. Kim’s expertise includes vascular and cell biology. He is a member of the American Heart Association and the North American Vascular Biology Organization.

Dr. Kim earned two bachelor’s degrees and a master’s degree from Sogang University in South Korea and his doctorate in molecular and cell biology from the University of Florida in Gainesville. He completed postdoctoral training in Dr. Paul Oh’s laboratory at the University of Florida and Barrow Neurological Institute.

Dr. Kim’s research interests include delineating molecular mechanisms underlying the development of vascular malformations associated with a genetic vascular disease called hereditary hemorrhagic telangiectasia (HHT). His goal is to discover more effective, more diverse, and safer drugs that can be clinically applicable to treat HHT patients.

Yong Hwan Kim

Yong Hwan Kim, PhD

Assistant Professor
Neurobiology

Yong Hwan Kim, PhD, is an assistant professor in the Department of Neurobiology at Barrow Neurological Institute. He works in the Barrow Aneurysm and AVM Research Center.

Dr. Kim’s expertise includes vascular and cell biology. He is a member of the American Heart Association and the North American Vascular Biology Organization.

Dr. Kim earned two bachelor’s degrees and a master’s degree from Sogang University in South Korea and his doctorate in molecular and cell biology from the University of Florida in Gainesville. He completed postdoctoral training in Dr. Paul Oh’s laboratory at the University of Florida and Barrow Neurological Institute.

Dr. Kim’s research interests include delineating molecular mechanisms underlying the development of vascular malformations associated with a genetic vascular disease called hereditary hemorrhagic telangiectasia (HHT). His goal is to discover more effective, more diverse, and safer drugs that can be clinically applicable to treat HHT patients.